UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call

UBS maintains a 'Buy' on CVS Caremark (NYSE: CVS) price target raised from $49 to $53.

Analyst, Steven Valiquette, said, "It remains quite interesting to us the extent to which the mgmt of CVS is trying to keep investor expectations in check in relation to upside from the Walgreen (NYSE: WAG) / Express Scripts (Nasdaq: ESRX) impasse, but our sense is a growing portion of this former WAG customer base is now likely more inclined to stay with CVS such that we raise our 2013 EPS estimate from $3.70 to $3.75 to reflect an extended retail benefit from the impasse." (UBS raises FY12 EPS estimate from $3.26 to $3.33)

"Shares of CVS appear poised to move higher near-term if there is no WAG/ESRX resolution. We believe there may be resolution over the next month or two, which could cause a temporary dip in CVS."

For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.

Shares of CVS Caremark closed at $45.92 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Adobe (ADBE) PT Lowered to $225 at UBS Amid Plans to Pivot to Freemium Model
• Oxford Industries (OXM) PT Lowered to $40 at UBS Amid Top-line Weakness
• Adobe (ADBE) PT Lowered to $379 at Bernstein SocGen Amid 'Increased Uncertainties'